Pimavanserin and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Pimavanserin
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Both buprenorphine (a pain and addiction medicine) and pimavanserin (used for Parkinson's-related hallucinations) can each affect your heart's electrical timing, something called the QT interval. When two medicines that do this are taken together, the effect can add up, which in rare cases can lead to an irregular heartbeat.
The good news is that this concern is theoretical, meaning it is based on how the drugs work rather than lots of real-world reports. Your care team can manage this safely by watching your heart rhythm and checking things like your potassium and magnesium. Please don't stop either medicine on your own, just talk with your doctor or pharmacist.
Effect: Additive QT-interval prolongation from concurrent buprenorphine and pimavanserin. Neither is a prodrug here; this is a pharmacodynamic (not metabolic) additive effect.
- Direction: Increased combined QT prolongation risk.
- Evidence: Theoretical; combined magnitude not established.
- Onset: Unspecified.
- Management: Avoid concomitant use where possible. If co-prescribed, assess and correct risk factors (hypokalemia, hypomagnesemia, bradycardia, CHF, baseline/congenital QT prolongation, recent AF conversion, digitalis therapy). Consider baseline and follow-up ECG and electrolyte monitoring.
Pimavanserin carries a known QT-prolongation label warning, reinforcing caution with other QT-prolonging agents.
What happens
An increased risk of QT interval prolongation
Interaction Deep Dive
The simultaneous administration of buprenorphine together with agents capable of prolonging the QT interval should be avoided342. It remains unknown what risk arises from pairing buprenorphine with other QT prolonging medications. When prescribing buprenorphine to individuals who present risk factors, including hypokalemia, bradycardia, recent conversion from atrial fibrillation, congestive heart failure, digitalis therapy, baseline QT prolongation, subclinical long-QT syndrome, or severe hypomagnesemia, clinicians should take these considerations into account in their decisions 1.
Why it happens (mechanism)
Additive QT interval prolongation
How to manage this interaction
Your care team can manage this by keeping a closer eye on your heart rhythm and bloodwork.
- Keep taking both medicines as prescribed unless your doctor tells you otherwise.
- Your team may check an ECG and your potassium and magnesium levels, and correct them if needed.
- Tell your prescriber if you have heart problems, a slow heartbeat, or a family history of heart-rhythm issues.
- Report symptoms like fainting, dizziness, or a fluttering or pounding heartbeat right away.
In some cases your doctor may choose an alternative medicine, but that decision is theirs to individualize for you.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Pimavanserin and Buprenorphine together?
Taking buprenorphine and pimavanserin together can add to the risk of QT prolongation, a heart-rhythm concern; keep taking both as prescribed and let your care team monitor your heart rhythm and electrolytes. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Pimavanserin and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Pimavanserin and Buprenorphine interaction managed?
Your care team can manage this by keeping a closer eye on your heart rhythm and bloodwork. Keep taking both medicines as prescribed unless your doctor tells you otherwise. Your team may check an ECG and your potassium and magnesium levels, and correct them if needed. Tell your prescriber if you have heart problems, a slow heartbeat, or a family history of heart-rhythm issues. Report symptoms like… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Pimavanserin or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (4)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: BUTRANS(R) transdermal system patch, buprenorphine transdermal system patch. Purdue Pharma L.P. (per FDA), Stamford, CT, 2016. DailyMed
- Product Information: BELBUCA(TM) buccal film, buprenorphine buccal film. Endo Pharmaceuticals Inc. (per FDA), Malvern, PA, 2016.
- Product Information: BUPRENEX(R) intravenous injection, intramuscular injection, buprenorphine HCl intravenous injection, intramuscular injection. Indivior Inc. (per DailyMed), Richmond, VA, 2016. DailyMed
Keep reading about Buprenorphine
Keep reading about Pimavanserin
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist